Keyphrases
Acute Myeloid Leukemia
8%
Allogeneic Bone Marrow Transplantation
14%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
Aplastic Anemia
7%
B Cells
9%
Bone Marrow
18%
Bone Marrow Transplantation
32%
Capillary Leak Syndrome
9%
CD8+ T Cells
8%
Childhood Cancer
9%
Chondromodulin-1
9%
Clinical Course
9%
Cyclosporine
9%
Etoposide
9%
Event-free Survival
16%
Ewing Sarcoma
90%
Ewing Sarcoma Family of Tumors
51%
EWS-FLI1
15%
Graft-versus-host Disease (GvHD)
18%
Granulocyte Colony-stimulating Factor (G-CSF)
29%
High Dose
9%
High Risk
10%
High-dose Chemotherapy
8%
HLA Matching
8%
HLA-A*02
8%
Interleukin-10
14%
Interleukin-2
29%
Interleukin-6
11%
Malignancy
14%
Melphalan
10%
Metastasis
9%
Natural Killer Cells
8%
Neuroblastoma
9%
Osteosarcoma
12%
Overall Survival
9%
Pediatric Oncology
10%
Poor Prognosis
8%
Primitive Neuroectodermal Tumor
10%
Pulmonary Alveolar Proteinosis
12%
Risk Factors
9%
Sarcoma Cells
8%
Solid Tumors
11%
T Cell Receptor
13%
T Cells
41%
Targeted Therapy
7%
Transgenic
18%
Transplantation
7%
Tumor
27%
Tumor Cells
12%
Tumor Patients
11%
Medicine and Dentistry
Allogeneic Stem Cell Transplantation
12%
Aplastic Anemia
7%
B Cell
10%
Bone Marrow Transplantation
24%
Cancer
12%
Cell Line
8%
Childhood Cancer
15%
Connective Tissue Cancer
6%
Cytokine
7%
Cytotoxic T-Cell
7%
Differential Diagnosis
6%
Disease Course
8%
Diseases
29%
DNA Microarray
7%
Drug Megadose
10%
Etoposide
8%
Event Free Survival
15%
Ewing Sarcoma
100%
Ganglioneuroblastoma
10%
Gene Expression
6%
Granulocyte Macrophage Colony Stimulating Factor
16%
High Dose Chemotherapy
8%
HLA-A
6%
Immunotherapy
8%
In Vitro
11%
Infection
10%
Interleukin 2
11%
Lung
8%
Lung Alveolus Proteinosis
10%
Malignant Neoplasm
5%
Melphalan
10%
Metastatic Carcinoma
13%
Neoplasm
36%
Osteosarcoma
6%
Overall Survival
11%
Pediatrics
16%
Pediatrics Patient
6%
Personalized Medicine
8%
Radiation Therapy
8%
Receptor
16%
Respiratory Failure
6%
Solid Malignant Neoplasm
11%
Stem Cell
13%
Stem Cell Therapy
6%
Survival Rate
6%
T Cell
32%
T Lymphocyte Receptor
9%
Targeted Therapy
7%
Tumor Cell
7%
Whole Body Radiation
6%
Immunology and Microbiology
Acute Graft Versus Host Disease
5%
Allogeneic Bone Marrow Transplantation
9%
Allogeneic Stem Cell Transplantation
10%
Aplastic Anemia
7%
Asthma
5%
B Cell
16%
Bone Marrow Transplantation
25%
Capillary
9%
CD3 Antigen
6%
Cell Function
5%
Cell Line
12%
Complement Activation
5%
Cyclophosphamide
5%
Cytokine
17%
Cytotoxic T Cell
6%
Cytotoxic T-Cell
10%
Dendritic Cell
7%
Drug Megadose
10%
Engraftment
7%
Epithelial Membrane Antigen
5%
Event Free Survival
6%
Fibroblast
5%
Gene Expression
6%
Graft-Versus-Host Disease
9%
Granulocyte Macrophage Colony-Stimulating Factor
12%
Immunotherapy
19%
Interleukin 10
8%
Interleukin 2
30%
Interleukin 6
8%
Interleukin 7
7%
Myeloid
10%
Natural Killer Cell
5%
Overall Survival
5%
Peptides
8%
Programmed Cell Death
6%
Stem Cell
10%
T Cell
56%
T Cell Activation
5%
T Cell Receptor
15%
T-Helper Cell
6%
Transgenics
24%
Tumor Antigen
6%
Tumor Cell
11%
Tumor Cell Line
6%
Tumor Necrosis Factor
5%
